Minerva Neurosciences (NERV) Free Cash Flow (2013 - 2026)

Minerva Neurosciences (NERV) has 14 years of Free Cash Flow data on file, last reported at -$5.4 million in Q1 2026.

• Quarterly Free Cash Flow fell 32.61% year-over-year to -$5.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$14.8 million (up 15.4% YoY) and the FY2025 annual result came in at -$13.5 million, up 30.95% from the prior year.
• Free Cash Flow fell to -$5.4 million in Q1 2026, from -$4.5 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of -$115407.0 in Q1 2023 to a low of -$9.5 million in Q3 2022.
• A 5-year average of -$4.6 million and a median of -$4.5 million in 2025 frame the typical range for Free Cash Flow.
• Annual changes were most pronounced in 2023 — Free Cash Flow soared 98.01% — and 2024, when it slumped 5180.68%.
• Tracing NERV's Free Cash Flow over 5 years: stood at -$4.1 million in 2022, then slumped by 45.77% to -$6.0 million in 2023, then grew by 13.76% to -$5.2 million in 2024, then advanced by 12.91% to -$4.5 million in 2025, then slipped by 20.0% to -$5.4 million in 2026.
• The last three Free Cash Flow figures came in at -$5.4 million (Q1 2026), -$4.5 million (Q4 2025), and -$2.9 million (Q3 2025), per Business Quant data.